The role of lipoprotein-associated phospholipase A2 as a marker and potential therapeutic target in atherosclerosis

Current Atherosclerosis Reports

Volumn 13, Issue 2, 2011, Pages 132-137

  Stewart, Ralph A H ^a   White, Harvey D ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

Atherosclerosis; Cardiovascular disease; Darapladib; Lp PLA2; Plaque stabilization

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DARAPLADIB; PLACEBO; SIMVASTATIN;

ATHEROGENESIS; ATHEROMA; ATHEROSCLEROTIC PLAQUE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ENDARTERECTOMY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIARRHEA; DISEASE MARKER; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDARTERECTOMY; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HEART DEATH; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; MORTALITY; NONHUMAN; PROTEIN FUNCTION; REVIEW; RISK FACTOR; RISK REDUCTION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANIMALS; ATHEROSCLEROSIS; BENZALDEHYDES; BIOLOGICAL MARKERS; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; OXIMES; PLAQUE, ATHEROSCLEROTIC; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 79955890428     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0158-8     Document Type: Review

References (23)

1. The Lp-PLA2 Studies Collaboration. Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 2010; 375:1536-1544. This is a comprehensive meta-analysis of epidemiologic and cohort studies that indicates that greater plasma Lp-PLA2 mass and activity are associated with an increased risk of coronary and vascular events.
2. Heart Protection Study Collaborative Group. Lipoprotein-associated phospholipase A2 activity and mass in relation to vascular disease and nonvascular mortality. J Intern Med 2010. doi:10.1111/j.1365-2796.2010.02258.x
3. Casas JP, Ninio E, Panayiotou A et al. PLA2G7 genotype, lipoprotein-associated phospholipase A2 activity, and coronary heart disease risk in 10 494 cases and 15 624 controls of European Ancestry. Circ 2010; 121(21):2284-2293.
4. 2 with darapladib will safely reduce the risk of cardiovascular events.
5. GlaxoSmithKline. The Stabilization Of pLaques usIng Darapladib- Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52). http://www.clinicaltrials.gov/ct2/show/NCT01000727?term= stabilization+of+plaques+AND+52&rank=1. Accessed 9-6-2010.
6. Asano K, Okamoto S, Fukunaga K et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 1999; 261(2):511-514. (Pubitemid 29392507)
7. Stafforini DM, Tjoelker LW, McCormick SP et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 1999; 274(11):7018-7024.
8. Macphee CH, Moores KE, Boyd HF et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J 1999; 338 ( Pt 2):479-487.
9. Matsumoto T, Kobayashi T, Kamata K. Role of lysophosphatidylcholine (LPC) in atherosclerosis. Curr Med Chem 2007; 14 (30):3209-3220.
10. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 2005; 25 (5):923-931. (Pubitemid 40627835)
11. Karakas M, Koenig W. Lp-PLA2 Inhibition-The Atherosclerosis Panacea? Pharmaceuticals 2010; 3(5):1360-1373.
12. Rosenson RS. Future role for selective phospholipase A2 inhibitors in the prevention of atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther 2009; 23(1):93-101.
13. Mannheim D, Herrmann J, Versari D et al. Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 2008; 39(5):1448-1455.
14. Herrmann J, Mannheim D, Wohlert C et al. Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome. Eur Heart J 2009; 30 (23):2930-2938.
15. Kolodgie FD, Burke AP, Skorija KS et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26(11):2523-2529. (Pubitemid 44607475)
16. Shi Y, Zhang P, Zhang L et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis 2007; 191(1):54-62. (Pubitemid 46227429)
17. Zhang SY, Shibata H, Karino K et al. Comprehensive evaluation of genetic and environmental factors influencing the plasma lipoprotein-associated phospholipase A2 activity in a Japanese population. Hypertens Res 2007; 30(5):403-409. (Pubitemid 46958890)
18. Liu PY, Li YH, Wu HL et al. Platelet-activating factoracetylhydrolase A379V (exon 11) gene polymorphism is an independent and functional risk factor for premature myocardial infarction. J Thromb Haemost 2006; 4(5):1023-1028.
19. Hou L, Chen S, Yu H et al. Associations of PLA2G7 gene polymorphisms with plasma lipoprotein-associated phospholipase A2 activity and coronary heart disease in a Chinese Han population: the Beijing atherosclerosis study. Hum Genet 2009; 125(1):11-20.
20. Wilensky RL, Shi Y, Mohler ER, III et al. Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 2008; 14 (10):1059-1066.
21. Johnson A, Zalewski A, Janmohamed S et al. Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, an emerging CV risk marker, can be inhibited in atherosclerotic lesions and plasma by novel pharmacologic intervention: The results of a multicenter clinical study. Circulation 110[17 (Suppl III)], III-590. 2004.
22. Mohler ER, III, Ballantyne CM, Davidson MH et al. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebocontrolled study. J Am Coll Cardiol 2008; 51(17):1632-1641. (Pubitemid 351635837)
23. Serruys PW, Garcia-Garcia HM, Buszman P et al. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circ 2008; 118 (11):1172-1182. The IBIS-2 clinical trial suggests that darapladib may reduce the size of the atheroma necrotic core assessed by intravascular ultrasound in patients with coronary artery disease.